Back to Agenda
Session 3: Navigate the GLP-1 Wave: PV Strategies for Consumer-Driven Use, Data, and Signals
Session Chair(s)
Vanessa Zapata
Associate Director, Global Clinical Safety & Pharmacovigilance Training Lead , Merck & Co., Inc., Canada
Stephanie Millican, PhD, MSc
Deputy Director Benefit Risk Evaluation, Safety and Surveillance, MHRA, United Kingdom
GLP-1 therapies are reshaping pharmacovigilance as consumer demand, real-world use, digital discussion, and nontraditional access channels accelerate safety-data generation. This panel will examine how pharma safety and epidemiology/RWE teams can interpret signals across spontaneous reports, social media, patient communities, telehealth pathways, compounded or counterfeit products, and real-world evidence, while managing the operational challenges created by unprecedented reporting volumes. Speakers will discuss how regional regulatory expectations and available guidance may differ across markets, and share practical lessons for separating signal from noise, communicating risk, and applying the GLP-1 experience to future consumer-driven medicines.
Learning Objective : At the conclusion of this session, participants should be able to: - Identify PV challenges created by consumer-driven GLP-1 use, reporting, and digital discussion
- Differentiate signal from noise across spontaneous reports, RWE, social media, and patient-generated data
- Apply practical considerations for risk communication and benefit-risk assessment in high-visibility GLP-1 settings
Have an account?